| Identification | Back Directory | [Name]
Neu-2000 | [CAS]
640290-67-1 | [Synonyms]
Neu-2000
Nelonemdaz
Benzoic acid, 2-hydroxy-5-[[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methyl]amino]- | [Molecular Formula]
C15H8F7NO3 | [MDL Number]
MFCD28502109 | [MOL File]
640290-67-1.mol | [Molecular Weight]
383.22 |
| Chemical Properties | Back Directory | [Boiling point ]
438.2±45.0 °C(Predicted) | [density ]
1.659±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 112.5 mg/mL (293.57 mM) | [form ]
Solid | [pka]
3.26±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Neu2000, is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. | [in vivo]
Nelonemdaz (0.5-20 mg/kg; i.v.) reduces cerebral infarct evolving 24 h after 60-mins occlusion of the middle cerebral artery occlusion (MCAO) substantially and dose dependently[1].
Nelonemdaz (5 mg/kg; i.v.) protects white matter such as axons and myelin as well as gray matter from ischemic brain injury[1].
| Animal Model: | Male Sprague-Dawley rats (260 to 300 g) (clip occlusion model)[1] | | Dosage: | 0.5-20 mg/kg | | Administration: | I.v. administration 5 mins after reperfusion | | Result: | Produced a large neuroprotective effect, with a maximal reduction in infarct volume of 66% at doses of 2.5 to 5 mg/kg.
Not observed neuronal damage in the most vulnerable cortical area after administration of 5 mg/kg.
|
| Animal Model: | Male Sprague-Dawley rats (260 to 300 g) (intraluminal thread occlusion model)[1] | | Dosage: | 5 mg/kg | | Administration: | I.v. administration 30 mins after reperfusion | | Result: | Did not change physiologic variables such as arterial pH, PCO2, PO2, and hematocrit.
Reduced infarct volume evolving in the cortex and the striatum substantially.
Reduced white matter damage in the striatum and external capsule markedly.
|
| [IC 50]
NMDA Receptor |
|
|